Non-alcoholic fatty liver disease (NAFLD) is a prevalent condition among patients with type 2 diabetes mellitus (T2DM) and has been identified as contributing significantly to increased cardiovascular disease risk and all-cause mortality. It has been. This finding from a recent nationwide population-based study in South Korea highlights the critical need for active management and consistent monitoring of NAFLD, even in mild cases, in patients with T2DM. There is.
Nationwide study abroad in Korea
The study, which leveraged data from the National Health Information Database and included more than 7 million participants, found a clear association between NAFLD and increased cardiovascular disease risk and all-cause mortality in patients with T2DM. Importantly, this risk also exists in patients with milder NAFLD. Participants in this study were divided into three groups based on NAFLD status and were followed for 8 to 13 years. (sauce)
Reconstitution of NAFLD: Metabolic Dysfunction Associated Fatty Liver Disease (MASLD)
NAFLD has now been reframed as metabolic dysfunction-associated fatty liver disease (MASLD), reflecting its complex relationship with metabolic dysfunction. A study by Kim et al. attempted to understand the impact of MASLD/NAFLD on cardiovascular disease and all-cause mortality in patients with type 2 diabetes. (sauce)
FibroTest: a potential biomarker of cardiovascular risk in T2D patients with NAFLD
In another study, researchers investigated whether biomarkers of NAFLD correlated with the degree of coronary artery calcification in T2D patients. They found that FibroTest scores were positively correlated with coronary artery calcium score (CACS) in both cohorts. Furthermore, this association persisted even after considering traditional cardiovascular risk factors, indicating that FibroTest may serve as a valuable biomarker of coronary artery calcification and cardiovascular risk in T2D patients. It was suggested. (sauce)
Prevalence of NAFLD in newly diagnosed T2DM patients
A study investigating the prevalence of NAFLD in newly diagnosed T2DM patients found alarming results. A study of 122 newly diagnosed T2DM patients found that NAFLD was diagnosed using ultrasound and 79% of patients had ultrasound steatosis at the time of T2DM diagnosis. . NAFLD patients had higher obesity, hypertension, AST, ALT, and FIB-4 scores. Of the patients referred to a hepatologist, 65% had severe steatosis, 22% had severe fibrosis, and 25% had advanced fibrosis. These findings highlight the urgent need for early management of her NAFLD with cost-effective screening and long-term monitoring. (source, source)
In conclusion, the impact of NAFLD, especially mild NAFLD, on the cardiovascular health of T2DM patients is significant. This means the need for active management and consistent monitoring of this disease. Furthermore, the potential use of biomarkers like FibroTest in cardiovascular risk assessment could revolutionize the management of NAFLD and T2DM. The high prevalence of her NAFLD in newly diagnosed T2DM patients further emphasizes the need for early detection and intervention. Doing so can help reduce the negative health effects associated with these interrelated conditions.
